The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay

European Journal of Pharmaceutical Sciences

Volumn 77, Issue , 2015, Pages 73-78

  Beig, Avital ^a   Agbaria, Riad ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Cyclodextrins; Intestinal permeability; Oral absorption; Solubility enabling formulation; Solubility permeability tradeoff

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMIODARONE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTIARRHYTHMIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; SBE7-BETA-CYCLODEXTRIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARENT PERMEABILITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOICHIOMETRY; THEORETICAL MODEL; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PERMEABILITY; SOLUBILITY;

ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; PERMEABILITY; RATS; SOLUBILITY;

EID: 84930960286     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.05.024     Document Type: Article

References (44)

1. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. A. Beig, J.M. Miller, and A. Dahan Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption Eur. J. Pharm. Biopharm. 81 2012 386 391
3. A. Beig, R. Agbaria, and A. Dahan Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations PLoS One 8 2013 e68237
4. A. Beig, J.M. Miller, and A. Dahan The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off Eur. J. Pharm. Biopharm. 85 2013 1293 1299
5. A. Beig, J.M. Miller, D. Lindley, R.A. Carr, P. Zocharski, R. Agbaria, and A. Dahan Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility-permeability interplay J. Pharm. Sci. 2015 in press
6. M. Bonati, F. Gaspari, V. D'Aranno, E. Benfenati, P. Neyroz, F. Galletti, and G. Tognoni Physicochemical and analytical characteristics of amiodarone J. Pharm. Sci. 73 1984 829 831
7. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666
8. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-gp: the role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharm. 6 2009 19 28
9. A. Dahan, and J. Miller The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J. 14 2012 244 251
10. A. Dahan, J. Miller, and G. Amidon Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 11 2009 740 746
11. A. Dahan, B.T. West, and G.L. Amidon Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur. J. Pharm. Sci. 36 2009 320 329
12. A. Dahan, J.M. Miller, A. Hoffman, G.E. Amidon, and G.L. Amidon The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J. Pharm. Sci. 99 2010 2739 2749
13. A. Dahan, A. Beig, V. Ioffe-Dahan, R. Agbaria, and J. Miller The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane AAPS J. 15 2013 347 353
14. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discovery 3 2004 1023 1035
15. A. Elgart, I. Cherniakov, Y. Aldouby, A. Domb, and A. Hoffman Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol Pharm. Res. 30 2013 3029 3044
16. M. Fairstein, R. Swissa, and A. Dahan Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine AAPS J. 15 2013 589 597
17. É. Fenyvesi, J. Szemán, K. Csabai, M. Malanga, and L. Szente Methyl-beta-cyclodextrins: the role of number and types of substituents in solubilizing power J. Pharm. Sci. 103 2014 1443 1452
18. K.J. Frank, K.M. Rosenblatt, U. Westedt, P. Hölig, J. Rosenberg, M. Mägerlein, G. Fricker, and M. Brandl Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement Int. J. Pharm. 437 2012 288 293
19. K.J. Frank, U. Westedt, K.M. Rosenblatt, P. Hölig, J. Rosenberg, M. Mägerlein, G. Fricker, and M. Brandl What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion? J. Pharm. Sci. 103 2014 1779 1786
20. M. Fukuda, D.A. Miller, N.A. Peppas, and J.W. McGinity Influence of sulfobutyl ether β-cyclodextrin (Captisol®) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion Int. J. Pharm. 350 2008 188 196
21. T. Higuchi, and K.A. Connors Phase-solubility techniques Adv. Anal. Chem. Instrum. 4 1965 117 212
22. T. Higuchi, and H. Kristiansen Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies J. Pharm. Sci. 59 1970 1601 1608
23. A.C. Jain, and M.C. Adeyeye Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol-SBE inclusion complexes Int. J. Pharm. 212 2001 177 186
24. A. Jain, A. Date, R.S. Pissurlenkar, E. Coutinho, and M. Nagarsenker Sulfobutyl ether7 β-cyclodextrin (SBE7 β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity AAPS PharmSciTech 12 2011 1163 1175
25. R. Kale, P. Tayade, M. Saraf, and A. Juvekar Molecular encapsulation of thalidomide with sulfobutyl ether-7 β-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice Drug Dev. Ind. Pharm. 34 2008 149 156
26. S.V. Kurkov, and T. Loftsson Cyclodextrins Int. J. Pharm. 453 2013 167 180
27. C. Lefeuvre, P. Le Corre, G. Dollo, F. Chevanne, J.L. Burgot, and R. Le Verge Biopharmaceutics and pharmacokinetics of 5-phenyl-1,2-dithiole-3-thione complexed with sulfobutyl ether-7-β-cyclodextrin in rabbits J. Pharm. Sci. 88 1999 1016 1020
28. H. Lennernäs, and B. Abrahamsson The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 57 2005 273 285
29. S.F. Lockwood, S. O'Malley, and G.L. Mosher Improved aqueous solubility of crystalline astaxanthin (3,3′-dihydroxy-β, β-carotene-4,4′-dione) by Captisol® (sulfobutyl ether β-cyclodextrin) J. Pharm. Sci. 92 2003 922 926
30. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1996 1017 1025
31. T. Loftsson, M.E. Brewster, and M. Masson Role of cyclodextrins in improving oral drug delivery Am. J. Drug Deliv. 2 2004 261
32. I. Lozoya-Agullo, M. Zur, O. Wolk, A. Beig, I. González-Álvarez, M. González-Álvarez, M. Merino-Sanjuán, M. Bermejo, and A. Dahan In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: investigation of the single-pass vs. the Doluisio experimental approaches Int. J. Pharm. 480 2015 1 7
33. J.M. Miller, and A. Dahan Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation Int. J. Pharm. 430 2012 388 391
34. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T.B. Borchardt, G.E. Amidon, G.L. Amidon, and A. Dahan The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharm. 8 2011 1848 1856
35. J.M. Miller, A. Beig, R.A. Carr, J.K. Spence, and A. Dahan A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol. Pharm. 9 2012 2009 2016
36. J.M. Miller, A. Beig, R.A. Carr, G.K. Webster, and A. Dahan The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations Mol. Pharm. 9 2012 581 590
37. Y. Nagase, M. Hirata, K. Wada, H. Arima, F. Hirayama, T. Irie, M. Kikuchi, and K. Uekama Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin Int. J. Pharm. 229 2001 163 172
38. K. Rajendrakumar, S. Madhusudan, and T. Pralhad Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat Eur. J. Pharm. Biopharm. 60 2005 39 46
39. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery J. Pharm. Sci. 85 1996 1142 1169
40. A.M. Totterman, N.G.M. Schipper, D.O. Thompson, and J.P. Mannermaa Intestinal Safety of Water-soluble β-Cyclodextrins in Paediatric Oral Solutions of Spironolactone: effects on Human Intestinal Epithelial Caco-2 Cells J. Pharm. Pharmacol. 49 1997 43 48
41. V. Zia, R.A. Rajewski, and V.J. Stella Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-β-CD to HP-β-CD Pharm. Res. 18 2001 667 673
42. M. Zur, N. Cohen, R. Agbaria, and A. Dahan The biopharmaceutics of successful controlled release product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract Int. J. Pharm. 489 2015 304 310
43. M. Zur, M. Gasparini, O. Wolk, G.L. Amidon, and A. Dahan The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol Mol. Pharm. 11 2014 1707 1714
44. M. Zur, A.S. Hanson, and A. Dahan The complexity of intestinal permeability: assigning the correct BCS classification through careful data interpretation Eur. J. Pharm. Sci. 61 2014 11 17